Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

44.4%

4 terminated/withdrawn out of 9 trials

Success Rate

42.9%

-43.6% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A

8(88.9%)

Phase 1

1(11.1%)

9Total

N/A(8)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT07339943Not ApplicableRecruiting

Micro-ultrasound-Guided Focal Laser Ablation for Intermediate-Risk Prostate Cancer: Safety & Effectiveness

Role: collaborator

NCT05296122Not ApplicableCompleted

Safety and Feasibility of MR-guided Laser Thermal Ablation of Brain Lesions

Role: lead

NCT03650595Not ApplicableRecruiting

MRI Guided Focal Laser Ablation of Prostate Cancer

Role: collaborator

NCT02702986Phase 1Completed

Safety and Feasibility of imILT Locally Advanced Pancreatic Cancer (LAPC)

Role: collaborator

NCT03187587Not ApplicableTerminated

Percutaneous Immunostimulating Interstitial Laser Thermotherapy in Pancreatic Cancer

Role: lead

NCT03039127Not ApplicableTerminated

Immunostimulating Interstitial Laser Thermotherapy in Breast Cancer

Role: lead

NCT02650492Not ApplicableTerminated

Immunostimulating Interstitial Laser Thermotherapy in Malignant Melanoma

Role: lead

NCT02973217Not ApplicableCompleted

Immunostimulating Interstitial Laser Thermotherapy in Pancreatic Cancer

Role: lead

NCT02690428Not ApplicableTerminated

Immunostimulating Interstitial Laser Thermotherapy in Solid Cancers

Role: lead

All 9 trials loaded